List view / Grid view
27 October 2015 | By Victoria White
A Phase 3 trial of lifitegrast met its primary endpoint of significantly improving patient-reported symptoms of dry eye disease from baseline to day 84...
27 October 2015 | By Victoria White
Omecamtiv mecarbil demonstrated statistically significant improvements in several measures of cardiac function, including systolic ejection time, stroke volume and N-terminal-pro-brain natriuretic peptide...
27 October 2015 | By Victoria White
A new study of more than 25,000 men has uncovered four new genetic variants associated with increased risk of testicular cancer...
27 October 2015 | By Victoria White
The license agreement includes the development and commercialisation of Constella for the treatment of irritable bowel syndrome with constipation and other gastrointestinal conditions...
26 October 2015 | By Victoria White
The Phase 2/3 KEYNOTE-010 trial compared two doses of Keytruda to docetaxel...
26 October 2015 | By Victoria White
If approved by the European Commission, Edurant will become available for the treatment of adolescents with HIV-1 for the first time...
26 October 2015 | By Victoria White
APR-246 combined with standard of care chemotherapy shows activity in the treatment of recurrent ovarian cancer...
26 October 2015 | By Victoria White
The approval was based on recently published clinical efficacy and safety data from a Phase 3 study which evaluated Yondelis versus the chemotherapy agent dacarbazine...
23 October 2015 | By Victoria White
BMS-955176 is a second-generation maturation inhibitor designed to inhibit one of the last steps of the HIV-1 viral lifecycle...
23 October 2015 | By Victoria White
Cosentyx Phase III studies have consistently demonstrated significant improvements in the signs and symptoms of ankylosing spondylitis and psoriatic arthritis...
23 October 2015 | By Victoria White
If approved by the European Commission, Imlygic would be the first in a class of novel agents known as oncolytic immunotherapies...
23 October 2015 | By HORIBA Scientific
HORIBA Scientific, global leader in Raman spectroscopy systems for over 50 years, announces the release of their new ProtectionPlus module for the acclaimed LabSpec 6 Spectroscopy Suite...
23 October 2015 | By Victoria White
The Phase III study evaluated the investigational use of Dysport for the treatment of spastic equinus foot, a condition associated with cerebral palsy in children aged 2-17...
23 October 2015 | By Victoria White
Isavuconazole will benefit from ten years of market exclusivity associated with orphan medicinal product status in the European Union...
23 October 2015 | By Victoria White
MHRA Enforcement officers seized nearly £1 million worth of unlicensed erectile dysfunction medicines from an address in Slough...
